Abstract
Recurrent primary biliary cirrhosis (PBC) is an important clinical outcome after liver transplantation (LT) in selected patients. Prevalence rates for recurrent PBC (rPBC) reported by individual LT programs range between 9% and 35%. The diagnostic hallmark of rPBC is histologic identification of granulomatous changes. Clinical and biochemical features are frequently absent with rPBC and cannot be used alone for diagnostic purposes. Some of the risk factors of rPBC may include recipient factors such as age, gender, HLA status and immunosuppression, as well as donor factors such as age, gender and ischemic time, although controversy exists. Most patients have early stage disease at the time of diagnosis, and there may be a role for therapy with ursodeoxycholic acid. While short- and medium-term outcomes remain favorable, especially if compared to patients transplanted for other indications, continued follow-up may identify reduced long-term graft and patient survival.
Original language | English (US) |
---|---|
Pages (from-to) | 720-726 |
Number of pages | 7 |
Journal | American Journal of Transplantation |
Volume | 10 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2010 |
Keywords
- Autoimmune liver disease
- Calcineurin inhibition
- OLT
- Orthotopic liver transplant
- Recurrent disease
ASJC Scopus subject areas
- Immunology and Allergy
- Transplantation
- Pharmacology (medical)